Barrier Therapeutics Company Description
Barrier Therapeutics wants to come between you and some nasty fungi. The company's diaper rash cream, sold in the US as Vusion, is its top product; the same treatment is marketed as Zimycan in Europe. Other key products include solar lentigines treatment Solagé (solar lentigines is the fancy name for skin blemishes known as "liver spots" or "sun spots") and seborrheic dermatitis (recurring skin rash) treatment Xolegel. The company acquires and in-licenses development-stage pharmaceuticals in order to complete the development process. It sells its products through an internal sales force. Barrier Therapeutics has been acquired by private dermatology products maker Stiefel Laboratories.
View the Comprehensive Company Description for Barrier Therapeutics
The Company Description provides a historical perspective of Barrier Therapeutics's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Barrier Therapeutics's evolution in the marketplace.
